ALECTOR INC

ALECNASDAQ

🏆 #3681 by market capEarnings Nov 4US Equity

$831.45▲ $23.70 (+2.85%)

Simulated price

🔔

Track ALEC

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$214M

Small Cap

📈Revenue Growth (YoY)

-79.1%

Declining

📊Gross Margin

-360.9%

Thin

💵FCF Margin

-1142.5%

Thin

⚖️P/S Ratio

15.4x

Expensive

Otter Score

Weak

No chart data available for ALEC.

Trading Snapshot

Day Range: $826.35 – $844.34
52-Week Range: $1.09 – $3.40
Volume: $2.14B
Avg Volume: $2.72B
Shares Outstanding: 111.0M
Next Earnings: Nov 12, 2026

Fundamentals Snapshot

Annual Revenue: $21M
Last Q Revenue: $3M
P/E Ratio: -1.8
P/S Ratio: 15.4x
EPS (TTM): $-1.06
Dividend Yield: 0.00%
Dilution (1yr): +4.8%

Why Investors Own ALEC

✓High-growth profile — revenue up +15.4% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALECTOR INC

ALEC

Financial Trends

Revenue

$21M▼ −79.1% YoY

Gross Margin

54.1%▼ −163.7% YoY

Operating Income

−$146M▲ +0.6% YoY

Free Cash Flow

−$184M▼ −20.4% YoY

Shares Outstanding

103.0M▲ +4.8% YoY

Net Cash

$30M▲ +$39M YoY

StockOtter · stockotter.space

About ALECTOR INC

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

🦦